Status:
COMPLETED
Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome
Lead Sponsor:
Joseph Calabrese, MD
Collaborating Sponsors:
Takeda Pharmaceuticals North America, Inc.
Conditions:
Depressive Disorder, Major
Metabolic Syndrome X
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The goal of this study is to begin to test whether or not pioglitazone, an FDA approved medication used to treat high blood sugar, may be safe and effective in treating Major Depressive Disorder (MDD)...
Eligibility Criteria
Inclusion
- Be male or female between the ages of 18 and 70
- DSM-IV diagnosis of major depressive disorder
- Currently depressed as confirmed by the MINI-Plus at the screening visit
- Quick Inventory of Depressive Symptomatology-Self-Report(QIDS-SR) score \> 11 at study baseline
- Meets criteria for the metabolic syndrome as defined by the NCEP ATP III criteria
Exclusion
- Pregnancy or breast feeding
- Unstable or inadequately treated medical illness as judged by the investigator
- Severe personality disorder
- Serious suicidal risk as judged by the investigator or having a score \> 2 on item 18 of the Inventory of Depressive Symptomatology-Clinician Rated (IDS-CR) scale
- Known history of intolerance or hypersensitivity to pioglitazone
- Treatment with pioglitazone in the 3 months prior to randomization
- Currently taking an antidiabetic/glucose-lowering agent. Antidiabetic agents that are prohibited include insulin, rosiglitazone, metformin, sitagliptin, sulfonylureas (e.g. glyburide, glipizide, glimepiride), non-sulfonylurea secretagogues (e.g. repaglinide, nateglinide), incretins (e.g. exenatide), and α-glucosidase inhibitors (e.g. acarbose, miglitol).
- Diagnosed with dementia
- Diagnosed with heart failure
- Transaminase elevation \>2.5 times the upper limit of normal
- Presence of renal impairment
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT00671515
Start Date
April 1 2008
End Date
November 1 2011
Last Update
January 26 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Cleveland Medical Center - Mood Disorders Program
Cleveland, Ohio, United States, 44106